Skyline Therapeutics, an F-Prime/Eight Roads investment, is a cell & gene therapy company developing novel genetic medicines across multiple therapeutic areas for global markets. The company has extensive R&D and manufacturing operations in Shanghai and affiliate offices in the U.S.
In August 2020, Occam recruited Gurpreet Ratra, PhD as the company’s CBO. Prior to joining Skyline, Gurpreet served as Head of Business Development at Spark Therapeutics.
About Occam Global
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.